Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.
Détails
ID Serval
serval:BIB_5E88F9AD4B4A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.
Périodique
Progress in Neuro-psychopharmacology and Biological Psychiatry
ISSN
0278-5846 (Print)
ISSN-L
0278-5846
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
32
Numéro
7
Pages
1722-1727
Langue
anglais
Notes
Publication types: Controlled Clinical Trial ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
BACKGROUND: Genetic variations of the dopamine and opioid receptors could influence the response to methadone maintenance treatment (MMT).
METHODS: We included 238 MMT patients according to their response to treatment and methadone dosing, along with 217 subjects without substance dependence. All were genotyped for polymorphisms of the dopamine D1, D2, micro-opioid and delta-opioid receptor genes.
RESULTS: The polymorphisms of the micro-opioid (118A>G), delta-opioid (921T>C), dopamine D1 (DdeI) and D2 (TaqI A) receptor genes were not associated with response to MMT and methadone dosing, whereas an association was found with the dopamine D2 receptor (DRD2) 957C>T polymorphism. The 957CC carriers were more frequently non-responders to treatment (OR=2.4; p=0.02) and presented a fourfold shorter period of negative urine screening (p=0.02). No significant differences in allele frequencies were observed between the MMT patients and the control group, suggesting no association of the analyzed polymorphisms with opioid dependence.
CONCLUSIONS: These results suggest that DRD2 genotype may contribute to the understanding of the interindividual variability to the response to MMT.
METHODS: We included 238 MMT patients according to their response to treatment and methadone dosing, along with 217 subjects without substance dependence. All were genotyped for polymorphisms of the dopamine D1, D2, micro-opioid and delta-opioid receptor genes.
RESULTS: The polymorphisms of the micro-opioid (118A>G), delta-opioid (921T>C), dopamine D1 (DdeI) and D2 (TaqI A) receptor genes were not associated with response to MMT and methadone dosing, whereas an association was found with the dopamine D2 receptor (DRD2) 957C>T polymorphism. The 957CC carriers were more frequently non-responders to treatment (OR=2.4; p=0.02) and presented a fourfold shorter period of negative urine screening (p=0.02). No significant differences in allele frequencies were observed between the MMT patients and the control group, suggesting no association of the analyzed polymorphisms with opioid dependence.
CONCLUSIONS: These results suggest that DRD2 genotype may contribute to the understanding of the interindividual variability to the response to MMT.
Mots-clé
Adult, Analysis of Variance, Female, Gene Frequency, Genetic Predisposition to Disease, Genotype, Heroin Dependence/drug therapy, Heroin Dependence/genetics, Humans, Male, Methadone/administration & dosage, Middle Aged, Narcotics/administration & dosage, Pharmacogenetics, Polymorphism, Genetic, Receptors, Dopamine D2/genetics, Receptors, Opioid/genetics
Pubmed
Web of science
Création de la notice
18/09/2008 15:47
Dernière modification de la notice
20/08/2019 14:16
Données d'usage
